Logo image of TNG.PA

TRANSGENE SA (TNG.PA) Stock Fundamental Analysis

EPA:TNG - Euronext Paris - Matif - FR0005175080 - Common Stock - Currency: EUR

0.664  +0 (+0.15%)

Fundamental Rating

2

TNG gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 69 industry peers in the Biotechnology industry. Both the profitability and financial health of TNG have multiple concerns. TNG is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TNG has reported negative net income.
In the past year TNG has reported a negative cash flow from operations.
TNG had negative earnings in each of the past 5 years.
In the past 5 years TNG always reported negative operating cash flow.
TNG.PA Yearly Net Income VS EBIT VS OCF VS FCFTNG.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M -40M

1.2 Ratios

TNG has a Return On Assets of -43.99%. This is comparable to the rest of the industry: TNG outperforms 43.48% of its industry peers.
Industry RankSector Rank
ROA -43.99%
ROE N/A
ROIC N/A
ROA(3y)-39.31%
ROA(5y)-30.88%
ROE(3y)-86.26%
ROE(5y)-64.34%
ROIC(3y)N/A
ROIC(5y)N/A
TNG.PA Yearly ROA, ROE, ROICTNG.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TNG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TNG.PA Yearly Profit, Operating, Gross MarginsTNG.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 -200 -300 -400

More info and screens

2

2. Health

2.1 Basic Checks

TNG does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TNG has more shares outstanding
TNG has more shares outstanding than it did 5 years ago.
TNG has a better debt/assets ratio than last year.
TNG.PA Yearly Shares OutstandingTNG.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
TNG.PA Yearly Total Debt VS Total AssetsTNG.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -3.98, we must say that TNG is in the distress zone and has some risk of bankruptcy.
TNG's Altman-Z score of -3.98 is on the low side compared to the rest of the industry. TNG is outperformed by 65.22% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.98
ROIC/WACCN/A
WACC7.73%
TNG.PA Yearly LT Debt VS Equity VS FCFTNG.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 1.57 indicates that TNG should not have too much problems paying its short term obligations.
TNG has a worse Current ratio (1.57) than 62.32% of its industry peers.
A Quick Ratio of 1.57 indicates that TNG should not have too much problems paying its short term obligations.
TNG has a Quick ratio (1.57) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.57
Quick Ratio 1.57
TNG.PA Yearly Current Assets VS Current LiabilitesTNG.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

TNG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.67%, which is quite impressive.
Looking at the last year, TNG shows a very negative growth in Revenue. The Revenue has decreased by -23.68% in the last year.
The Revenue has been growing slightly by 1.51% on average over the past years.
EPS 1Y (TTM)32.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-23.68%
Revenue growth 3Y-6.51%
Revenue growth 5Y1.51%
Sales Q2Q%N/A

3.2 Future

TNG is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.42% yearly.
TNG is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 44.72% yearly.
EPS Next Y28%
EPS Next 2Y46.52%
EPS Next 3Y0.88%
EPS Next 5Y2.42%
Revenue Next Year-44.69%
Revenue Next 2Y55.17%
Revenue Next 3Y-6.48%
Revenue Next 5Y44.72%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TNG.PA Yearly Revenue VS EstimatesTNG.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
TNG.PA Yearly EPS VS EstimatesTNG.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 -1

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TNG. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 11.95, the valuation of TNG can be described as reasonable.
TNG's Price/Forward Earnings ratio is rather cheap when compared to the industry. TNG is cheaper than 92.75% of the companies in the same industry.
TNG is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 21.98, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 11.95
TNG.PA Price Earnings VS Forward Price EarningsTNG.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNG.PA Per share dataTNG.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.52%
EPS Next 3Y0.88%

More info and screens

0

5. Dividend

5.1 Amount

TNG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRANSGENE SA

EPA:TNG (3/26/2025, 7:00:00 PM)

0.664

+0 (+0.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07
Earnings (Next)03-27 2025-03-27/amc
Inst Owners0.93%
Inst Owner ChangeN/A
Ins Owners0.7%
Ins Owner ChangeN/A
Market Cap87.84M
Analysts82.86
Price Target1.73 (160.54%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-42.04%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)11.48%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-43.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 11.95
P/S 11.51
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.22
EYN/A
EPS(NY)0.06
Fwd EY8.37%
FCF(TTM)-0.29
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS0.06
BVpS0
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -43.99%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.31%
ROA(5y)-30.88%
ROE(3y)-86.26%
ROE(5y)-64.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 237.06%
Cap/Sales 42.82%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.57
Quick Ratio 1.57
Altman-Z -3.98
F-Score3
WACC7.73%
ROIC/WACCN/A
Cap/Depr(3y)95.02%
Cap/Depr(5y)109.94%
Cap/Sales(3y)17.95%
Cap/Sales(5y)15.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y28%
EPS Next 2Y46.52%
EPS Next 3Y0.88%
EPS Next 5Y2.42%
Revenue 1Y (TTM)-23.68%
Revenue growth 3Y-6.51%
Revenue growth 5Y1.51%
Sales Q2Q%N/A
Revenue Next Year-44.69%
Revenue Next 2Y55.17%
Revenue Next 3Y-6.48%
Revenue Next 5Y44.72%
EBIT growth 1Y-0.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.32%
EBIT Next 3Y-16.81%
EBIT Next 5YN/A
FCF growth 1Y-157.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-143.79%
OCF growth 3YN/A
OCF growth 5YN/A